When Does Tissue Processing Cross the Regulatory Line and Require Pre-Market Review?

By Frederick R. Ball, Coleen W. Hill and Kelechi Anyatonwu

For developers of human cells, tissues, and cellular and tissue-based products, classification can determine the shape of an entire regulatory strategy and ultimately how to get that product to market. Is a product regulated solely under Section 361 of the Public Health Service Act, or does it require pre-market review as a drug, biological product or medical device? A recent decision out of the U.S. District Court for the Northern District of Georgia, MiMedx Group, Inc. v. FDA, offers a timely insight into how courts may scrutinize FDA’s answers to those questions.

Read the full Alert on the Duane Morris LLP website.

© 2009- Duane Morris LLP. Duane Morris is a registered service mark of Duane Morris LLP.

The opinions expressed on this blog are those of the author and are not to be construed as legal advice.

Proudly powered by WordPress